Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Repligen Corp (RGEN) -- Ignore unavailable to you. Want to Upgrade?

To: VIXandMore who wrote (278)	9/17/2003 10:01:04 AM
From: RMP	Respond to of 395

7:17AM Repligen Corp: WR Hambrecht reits Buy following disappointing patent news (RGEN) 8.26: After the close, Repligen announced that it lost its Court challenge to Bristol-Myer's inventorship of several CTLA4-Ig patents. Although co also announced a separate allowance of a patent which potentially blocks Bristol-Myers, WR Hambrecht believes that the chances of a potential settlement with Bristol-Myers are seriously diminished. While firm assigned a high probability to a settlement, it was not included in firm's estimates or valuation. WR Hambrecht continues to believe that the key driver for the stock is the anticipated announcement of Phase III clinical trial results for Secretin in autism in Dec. Anyone listen to the CC?